Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Candel Therapeutics plans to test Bionaut’s tiny robots to treat brain tumors

By Brian Buntz | December 15, 2021

Bionaut Labs Candel Therapeutics tiny robotsThe VC-backed microrobotics startup Bionaut Labs has entered into a strategic collaboration with Candel Therapeutics.

Candel (NSDQ:CADL) — a biopharma focused on oncolytic viral immunotherapies — will explore the use of Bionaut Labs’ miniature remote-controlled robots. Could the robots help deliver Candel’s oncolytic viral immunotherapy agents to certain brain tumors?

Founded in 2016, Bionaut Labs has focused on developing new modalities for treating central nervous system disorders since its inception.

Now, Bionaut will work with Candel to further the preclinical development of a micro-robotic system that can deliver oncolytic viruses directly to brain tumors, including high-grade gliomas.

“Bionaut designed its platform to provide accurate and safe access to hard-to-reach locations in the CNS,” said Michael Shpigelmacher, Bionaut Labs’ CEO.

Executives at Bionaut were impressed with Candel’s presence in the field of oncolytic viral immunotherapy for treatment of a variety of cancers, in particular glioblastoma multiforme. “Together with Candel, we hope to deliver a unique one-two punch, by providing the required precision on both the anatomical and biochemical level, to advance the treatment for more patients suffering from brain cancers and avoid invasive treatment procedures,” Shpigelmacher said. “Candel’s promising clinical data makes it stand out as an excellent partner for Bionaut Labs.”

Both firms will retain rights to their platforms and the right to pursue future collaboration.

“The research we plan to jointly undertake validates our approach and will enable advancement of our technology as we continue our mission of helping patients suffering from debilitating brain diseases who lack effective treatments,” Bionaut Labs CEO, Michael Shpigelmacher said in a press release.

The companies did not disclose the financial terms of the agreement.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
Tagged With: Bionaut Labs, Candel Therapeutics, immunotherapy
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE